U of R demonstrates HIV testing program
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
40 minutes ago
- CTV News
Manitoba reaches settlement with family of woman who died after halted medical flight
An empty bed is seen at a hospital in Sarnia, Ont., on Wednesday, January 26, 2022. THE CANADIAN PRESS/Chris Young WINNIPEG — The Manitoba government says it has settled a lawsuit with the family of a woman who died during the COVID-19 pandemic while in the process of being transferred out of province due to a shortage of hospital beds. Matt Wiebe, minister of justice and the province's attorney general, confirmed a settlement was recently reached with the family of Krystal Mousseau more than two years after Mousseau's mother first sued the provincial government and health agencies. Elaine Mousseau alleged that cuts to health care and improper medical decisions contributed to her daughter's death in May 2021. Mousseau was in intensive care with severe COVID-19 pneumonia and died after being taken by ambulance to a waiting airplane that was to take her to Ottawa. Details of the settlement were not made available. Wiebe says he is pleased the province has been able to reach an agreement with the Mousseau family. 'While it can't bring back their loved one or repair the harms done to their family, we hope this agreement brings them clarity and a sense of closure,' Wiebe said in a statement on Friday. 'Our government remains committed to rebuilding health care in northern Manitoba and across our province.' Mousseau died on May 25, 2021, after an aborted attempt to fly her from an intensive care unit in Brandon, Man., to a hospital in Ottawa. The province, under the previous Progressive Conservative government, sent dozens of intensive-care patients to other provinces that spring due to a shortage of beds as COVID-19 cases rose and hospitals struggled to deal with an influx of people needing care. Elaine Mousseau alleged that the government and Shared Health, the provincial body that co-ordinates many health services, failed to provide proper care. Shared Health said on Friday that any settlement is confidential in nature and it would not be commenting on the matter. Elaine Mousseau's lawyer was not immediately made available to comment on the settlement. A letter from the regional authority in western Manitoba to the family shortly after Krystal Mousseau's death, which was released publicly, said the transport team did not have a piece of equipment that would let them constantly monitor Mousseau's blood pressure, so a blood-pressure cuff was used instead. Mousseau was also being given at least one medication at the wrong rate, the letter stated. The lawsuit alleged the Tory government ignored warnings in 2019 when it privatized some air ambulance services. The government also created a scenario where hospitals couldn't deal with an influx of patients when it reduced the number of critical care beds in 2019, the lawsuit claimed. The statement of claim also alleged staff at the hospital allowed Mousseau to leave while she was in unstable condition and at severe risk. Mousseau showed high blood pressure and a sudden elevated heart rate shortly before she was put into the ambulance on the way to the airport, the statement of claim alleged. She went into cardiac arrest while in the ambulance, was sent back to hospital, and suffered another cardiac arrest and multiple organ failure before being pronounced dead the next day, the document said. This report by The Canadian Press was first published July 25, 2025. Brittany Hobson, The Canadian Press
CBC
2 hours ago
- CBC
Wildfire smoke chokes northern Manitoba air, while hot, humid weather plagues the south
Social Sharing As a large swath of Manitoba deals with heavy wildfire smoke polluting the air, others in the province are starting the weekend amidst suffocating heat and humid conditions. Environment and Climate Change Canada has issued an air quality warning for much of northern Manitoba including Thompson, The Pas and Flin Flon on Saturday morning. With relatively light winds, smoke is expected to concentrate especially over the area near active wildfires, causing poor air quality and reduced visibility throughout the day. Everyone's health is at risk, regardless of age or health status, during heavy smoke conditions, the federal agency said. But pregnant people, children, seniors and those with underlying health conditions are more likely to be impacted. Environment Canada is advising people to reschedule or cancel outdoor sports and activities. People who work outdoors should avoid extraneous activities and seek medical attention if experiencing symptoms. Those may include eye eye, nose and throat irritation, headaches or a mild cough. More less common symptoms include wheezing, chest pains or severe cough, Environment Canada said. According to the province's latest fire bulletin, issued Friday, the Manitoba Wildfire Service was responding to 121 active wildfires across the province, which has seen a total of 337 wildfires to date, well above the average for this time of year of 260. Heat warning Meanwhile, pockets of southern Manitoba, including the cities of Winnipeg, Brandon and Portage la Prairie, are under a heat warning. Humid and hot conditions are expected to remain throughout Saturday with temperatures reaching the low 30's C and humidex values nearing 38, Environment Canada said. Conditions are expected to improve with a cold front moving overnight Saturday, but in the meantime the weather agency is advising people to watch for signs of early heat exhaustion including headache, dizziness and intense fatigue. Extreme heat can affect everyone's health, but the risks are greater for older adults and other vulnerable people, Environment Canada said. To reduce the health effects of heat, stay out of direct sunlight, drink plenty of water and stay in a cool space, closing blinds and open windows if it is cooler outside than inside or turning on air conditioning. The weather agency also advises people to ensure children and pets are never left alone in closed vehicles.
Globe and Mail
2 hours ago
- Globe and Mail
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
We expect investors to focus on Altimmune 's ALT progress in the studies evaluating its lead pipeline candidate, pemvidutide, when it reports second-quarter 2025 results. Since ALT lacks a marketed drug in its portfolio, we do not expect it to record revenues. The Zacks Consensus Estimate for the bottom line is pegged at a loss of 32 cents per share. Let's see how things might have shaped up before the announcement. Factors Likely to Influence ALT's Q2 Results Altimmune's lead pipeline candidate, pemvidutide, a novel, peptide-based GLP-1/glucagon dual receptor agonist, is currently being developed for treating obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol liver disease (ALD) and alcohol use disorder (AUD). Last month, the company announced top-line data from the phase IIb IMPACT study, which evaluated pemvidutide for treating MASH. The primary endpoints of the study were to achieve MASH resolution without a worsening of fibrosis and to improve fibrosis without a worsening of MASH. In an intent-to-treat (ITT) analysis, at 24 weeks, MASH resolution without fibrosis worsening was achieved by 59.1% and 52.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, compared to 19.1% with placebo. Meanwhile, in the ITT analysis, fibrosis improvement without MASH worsening was seen in 31.8% and 34.5% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, versus 25.9% with placebo. However, these differences were not statistically significant. Shares of the company tanked on this news. Participants who received pemvidutide experienced an average weight loss of 5% with the 1.2 mg dose and 6.2% with the 1.8 mg dose, compared to 1% in the placebo group at 24 weeks. Treatment with pemvidutide was generally safe and well-tolerated. Investors will be keen to get more updates on the development path ahead for pemvidutide on the upcoming earnings call. Year to date, shares of Altimmune have plunged 43% against the industry's increase of 7.2%. Altimmune recently initiated two separate phase II studies on pemvidutide for the treatment of AUD and ALD. Further updates on these studies are expected on the upcoming earnings call. Operating expenses are most likely to have declined in the to-be-reported quarter due to the timing of clinical study costs. ALT's Earnings Surprise History Altimmune has a mixed earnings surprise history, beating estimates in three of the trailing four quarters and missing the same on the remaining occasion, the average surprise being 9.21%. In the last reported quarter, ALT posted an earnings surprise of 25.71%. Altimmune, Inc. Price and EPS Surprise What Our Model Predicts for ALT Stock Our proven model does not conclusively predict an earnings beat for Altimmune this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. ALT's Earnings ESP: Altimmune has an Earnings ESP of 0.00% as both the Most Accurate Estimate and Zacks Consensus Estimate are pegged at a loss of 32 cents per share. ALT's Zacks Rank: Altimmune has a Zacks Rank #3 at present. You can see the complete list of today's Zacks #1 Rank stocks here. Stocks With the Favorable Combination Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle. Akero Therapeutics AKRO has an Earnings ESP of +0.53% and a Zacks Rank #1 at present. AKRO stock has surged 81.5% year to date. Akero beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 48.90%. Exact Sciences EXAS has an Earnings ESP of +475.00% and a Zacks Rank #2 at present. Shares of EXAS have declined 13.5% year to date. EXAS beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 48.79%. Exact Sciences is scheduled to report second-quarter results on Aug. 6, after market close. Alkermes ALKS has an Earnings ESP of +4.94% and a Zacks Rank #3 at present. Shares of ALKS have lost 7.8% year to date. ALKS beat on earnings in one of the last four quarters and missed in the other three, delivering an average negative surprise of 8.24%. Alkermes will report second-quarter results on July 29, before market open. #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS): Free Stock Analysis Report Altimmune, Inc. (ALT): Free Stock Analysis Report Exact Sciences Corporation (EXAS): Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO): Free Stock Analysis Report
